论文部分内容阅读
【据J Hepatol 2012年2月报道】题:brivanib作为一线药物治疗晚期肝细胞癌的II期开放性研究【(作者Finn RS等)肝硬化是肝细胞癌(HCC)发展过程中主要的危险因素,随着肝硬化患者生存期的改善,世界各地报道的HCC病例正随之增加。早期的HCC可以通过手术切除、经皮消融或肝移植这些治愈性手段来治疗,但大多数的HCC诊断之初即已处于晚期,此时治愈性治疗方式并不适用,因而死亡率很高。在过去的几年里,基于对HCC分子病理新的全面认识,新的治疗手
[According to J Hepatol, February 2012] Title: Phase II open-label study of brivanib as first-line drug in the treatment of advanced hepatocellular carcinoma [(Finn RS, et al)] Liver cirrhosis is a major risk factor in the development of hepatocellular carcinoma (HCC) As the survival of cirrhotic patients improves, the number of HCC cases reported throughout the world is increasing. Early HCC can be treated by such curative techniques as surgical resection, percutaneous ablation, or liver transplantation. However, most of the patients with HCC are diagnosed early, and the curative treatment is not suitable at this time. Therefore, the mortality rate is high. In the past few years, based on a new comprehensive understanding of HCC molecular pathology, new therapeutic hands